Biofrontera (BFRI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting formally called to order with directors and key executives introduced via remote communication.
Agenda and rules of conduct made available to attendees; meeting recording restricted to company only.
Board and executive committee updates
Directors in attendance included John Borer, Beth Hoffman, and Heikki Lanckriet.
Key executives present: CEO, CFO, Chief Commercial Officer, legal counsel, and Inspector of Elections.
Shareholder proposals
Three proposals presented: election of two Class II directors, amendment of the 2021 Omnibus Incentive Plan, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biofrontera
- Q2 2026 revenue up 32.9% with margin gains, but legal and capital risks remain.BFRI
Q2 2026 - Revenue and margins are rising as new indications and regulatory milestones drive future growth.BFRILytham Partners Spring 2026 Investor Conference
- Q1 2026 saw 17% revenue growth, 80% gross margin, and clinical and legal developments.BFRIQ1 2026
- Stockholders will vote on director elections, incentive plan expansion, and auditor ratification.BFRIProxy filing
- Healthcare innovators project strong growth through new indications, acquisitions, and market expansion.BFRI2nd Annual Lytham Partners Healthcare Investor Summit
- Record revenues, margin expansion, and Q4 profitability set the stage for 2026 growth.BFRIQ4 2025
- Q2 revenue up 34%, net loss narrowed, debt eliminated, and new launches support growth.BFRIQ2 2024
- Revenue up 9% to $8.6M, net loss narrowed, but liquidity and Nasdaq risks persist.BFRIQ1 2025
- Record sales and clinical milestones set the stage for margin gains and growth in 2025.BFRIQ4 2024